|
시장보고서
상품코드
1463157
항비만 약물 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 작용기전별, 제품별, 유통채널별, 지역별, 부문별 예측(2024-2032년)Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면, 세계 항비만 약물 시장 규모는 2032년까지 734억 7,085만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
항비만 약물은 건강한 체중을 달성하고 유지하기 위해 식단 조절이나 신체 활동과 같은 생활습관 개선만으로는 충분하지 않은 경우, 특히 개인의 잉여 체중을 조절하고 감소시키는 데 도움을 주기 위해 만들어진 의약품 물질입니다. 이러한 의약품은 신진대사 조절, 지방 흡수 억제, 식욕 억제 등 다양한 메커니즘을 통해 작용합니다. 의료진은 일반적으로 체질량지수(BMI)가 높은 환자나 2형 당뇨병과 같은 비만 관련 건강 문제를 가진 환자 등 특정 기준을 충족하는 환자에게 처방합니다.
항비만 약물 시장은 체중 조절에 대한 사회적 인식의 변화, 전 세계 비만율 증가, 의약품 연구 발전 등의 요인에 영향을 받아 시간이 지남에 따라 다양한 성장세를 보이고 있습니다. 최근에는 비만과 관련된 건강 위험에 대한 인식이 높아지고 보다 효율적이고 안전한 치료 옵션에 대한 수요가 증가함에 따라 이 시장에 대한 관심이 다시 증가하고 있습니다. 이 시장은 체중 감량 결과를 개선하고 부작용을 최소화하기 위해 병용 요법을 포함한 새로운 약물을 도입하는 것을 목격했습니다. 또한, 의료 서비스 제공업체들은 생활습관 개선, 행동 중재 및 약물 치료를 포함한 종합적인 비만 관리 접근법을 중요시하고 있습니다.
또한, 전 세계적으로 비만 유병률이 증가하고 관련 건강 위험에 대한 인식이 높아짐에 따라 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 의약품 개발 기술의 발전은 효능과 안전성 프로파일을 개선한 새로운 의약품을 도입할 수 있는 기회를 제공합니다. 또한, 체중 관리에 대한 사회적 인식의 변화와 예방적 건강관리에 대한 중요성이 높아지면서 시장 성장을 가속할 것으로 예상됩니다. 또한, 디지털 건강 솔루션과 개인 맞춤형 의료 접근법의 통합은 개별 환자의 필요에 따라 치료를 맞춤화할 수 있는 길을 제공하여 시장 범위를 확대할 수 있습니다. 또한, 제약회사와 의료 서비스 제공업체 간의 전략적 제휴와 연구개발에 대한 투자 증가는 역동적으로 변화하는 시장 환경에서 더 많은 비즈니스 기회를 창출할 것으로 보입니다.
항비만약 시장 보고서 하이라이트
2023년, 말초 작용 항비만 약물 부문은 영양 흡수를 개선하고 배고픔을 줄이는 메커니즘의 능력으로 인해 가장 큰 매출 점유율을 차지했습니다.
2023년에는 소매 약국 부문이 큰 매출 점유율을 차지할 것으로 예상됩니다. 이러한 매장은 소비자에게 의약품에 대한 편리한 접근성을 제공하며 일반적으로 지역 내 접근이 용이한 곳에 위치합니다.
2023년 북미는 높은 비만율과 정부 지원 정책 등 다양한 요인으로 인해 가장 큰 시장 점유율을 차지했습니다. 또한, 제약 대기업의 합병, 인수, 제휴 등의 전략적 움직임은 경쟁 구도 형성에 매우 중요한 역할을 하고 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 항비만 약물 시장 인사이트
- 항비만 약물 시장 - 유통 채널 현황
- 항비만 약물 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTEL 분석
- 항비만 약물 시장 유통 채널 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 제품별 세계 시장
- 주요 조사 결과
- 서론
- 미공인
- 승인
제6장 작용기전별 세계 시장
- 주요 조사 결과
- 서론
- 중추 작용제
- 말초 작용제
제7장 유통 채널별 세계 시장
- 주요 조사 결과
- 서론
- 병원 약국
- 소매 약국
- 기타
제8장 지역별 세계 시장
- 주요 조사 결과
- 서론
- 항비만 약물 시장 평가, 지역별, 2019-2032년
- 항비만 약물 시장 - 북미
- 북미 : 항비만 약물 시장, 제품별, 2019년-2032년
- 북미 : 항비만 약물 시장, 유통 채널별, 2019년-2032년
- 북미 : 항비만 약물 시장, 작용기전별, 2019년-2032년
- 항비만 약물 시장 - 미국
- 항비만 약물 시장 - 캐나다
- 항비만 약물 시장 - 유럽
- 유럽 : 항비만 약물 시장, 제품별, 2019년-2032년
- 유럽 : 항비만 약물 시장, 유통 채널별, 2019년-2032년
- 유럽 : 항비만 약물 시장, 작용기전별, 2019년-2032년
- 항비만 약물 시장 - 영국
- 항비만 약물 시장 - 프랑스
- 항비만 약물 시장 - 독일
- 항비만 약물 시장 - 이탈리아
- 항비만 약물 시장 - 스페인
- 항비만 약물 시장 - 네덜란드
- 항비만 약물 시장 - 러시아
- 항비만 약물 시장 - 아시아태평양
- 아시아태평양 : 항비만 약물 시장, 제품별, 2019년-2032년
- 아시아태평양 : 항비만 약물 시장, 유통 채널별, 2019년-2032년
- 아시아태평양 : 항비만 약물 시장, 작용기전별, 2019년-2032년
- 항비만 약물 시장 - 중국
- 항비만 약물 시장 - 인도
- 항비만 약물 시장 - 말레이시아
- 항비만 약물 시장 - 일본
- 항비만 약물 시장 - 인도네시아
- 항비만 약물 시장 - 한국
- 항비만 약물 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 항비만 약물 시장, 제품별, 2019-2032년
- 중동 및 아프리카 : 항비만 약물 시장, 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 항비만 약물 시장, 작용기전별, 2019-2032년
- 항비만 약물 시장 - 사우디아라비아
- 항비만 약물 시장 - 아랍에미리트(UAE)
- 항비만 약물 시장 - 이스라엘
- 항비만 약물 시장 - 남아프리카
- 항비만 약물 시장 - 라틴아메리카
- 라틴아메리카 : 항비만 약물 시장, 제품별, 2019년-2032년
- 라틴아메리카 : 항비만 약물 시장, 유통 채널별, 2019년-2032년
- 라틴아메리카 : 항비만 약물 시장, 작용기전별, 2019년-2032년
- 항비만 약물 시장 - 멕시코
- 항비만 약물 시장 - 브라질
- 항비만 약물 시장 - 아르헨티나
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 파트너십/협업/계약/공개
제10장 기업 개요
- Boehringer Ingelheim International GmbH
- Currax Pharmaceuticals
- Gelesis
- GlaxoSmithKline plc
- Kintai Therapeutics
- Novartis AG
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc
- VIVUS LLC
The global anti-obesity medication market size is expected to reach USD 73,470.85 million by 2032, according to a new study by Polaris Market Research. The report "Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Anti-obesity medications are pharmaceutical substances crafted to aid individuals in controlling and reducing their surplus body weight, particularly when lifestyle modifications like dietary adjustments and physical activity alone prove insufficient for attaining and sustaining a healthy weight. These medications can operate through diverse mechanisms, such as modifying metabolism, inhibiting fat absorption, and suppressing appetite. Healthcare providers typically prescribe them to patients meeting specific criteria, such as those with elevated body mass index (BMI) or obesity-related health issues like type 2 diabetes.
The market for anti-obesity medication has experienced variable growth over time, influenced by factors such as shifting societal perceptions regarding weight management, the global escalation in obesity rates, and advancements in pharmaceutical research. In recent times, there has been a resurgence of interest in this market, spurred by heightened awareness of the health hazards linked to obesity and the demand for more efficient and safe treatment options. The market has witnessed the introduction of novel medications, including combination therapies, aimed at improving weight loss outcomes and minimizing adverse effects. Furthermore, healthcare providers are increasingly emphasizing a comprehensive approach to managing obesity, encompassing lifestyle modifications, behavioral interventions, and pharmaceutical treatments.
Additionally, with a rising prevalence of obesity worldwide and an increasing awareness of associated health risks, there is a growing demand for effective treatment options. Advancements in drug development technologies present opportunities for the introduction of novel medications with improved efficacy and safety profiles. Additionally, shifting societal attitudes towards weight management and the growing emphasis on preventive healthcare are expected to drive market growth. Moreover, the integration of digital health solutions and personalized medicine approaches offers avenues for tailoring treatments to individual patient needs, thereby expanding market reach. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers, as well as increased investment in research and development, are poised to unlock further opportunities in this dynamic and evolving market landscape.
Anti-Obesity Medication Market Report Highlights
In 2023, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share, due to the mechanism's ability to improve nutrient absorption and reduce feelings of hunger.
In 2023, the retail pharmacies segment emerged as the significant revenue share. These outlets provide convenient access to medications for consumers and are commonly located in easily accessible areas within communities.
In 2023, the North American region dominated the largest market share due to various factors, such as the high prevalence of obesity and supportive government policies. Additionally, strategic maneuvers like mergers, acquisitions, and partnerships among pharmaceutical giants play a pivotal role in shaping the competitive landscape.
The global key market players include Boehringer Ingelheim International GmbH, Currax Pharmaceuticals, Gelesis, GlaxoSmithKline plc, Kintai Therapeutics, Novartis AG, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., VIVUS LLC.
Polaris Market Research has segmented the Anti-Obesity Medication market report based on mechanism of action, product, distribution channel, and region:
Anti-Obesity Medication, Mechanism of Action Outlook (Revenue - USD Million, 2019 - 2032)
- Centrally Acting Drugs
- Peripherally Acting Drugs
Anti-Obesity Medication, Product Outlook (Revenue - USD Million, 2019 - 2032)
- Off Label
- Semaglutide (Wegovy)
- Topiramate (Xenical Alli)
- Dulaglutide (Trulicity)
- Liraglutide (Semaglutide (Wegovy))
- Others
- Approved
- Liraglutide (Orlistat)
- Bupropion-naltrexone (Contrave)
- Orlistat
- Alli
- Xenical
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy
Anti-Obesity Medication, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Anti-Obesity Medication, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Anti-Obesity Medication Market Insights
- 4.1. Anti-Obesity Medication Market - Distribution Channel Snapshot
- 4.2. Anti-Obesity Medication Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. The increasing incidence of obesity
- 4.2.1.2. A rise in the occurrence of childhood obesity and morbid obesity
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of long-term effectiveness data
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Anti-Obesity Medication Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Anti-Obesity Medication Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 5.3. Off Label
- 5.3.1. Global Anti-Obesity Medication Market, by Off Label, by Region, 2019-2032 (USD Million)
- 5.3.2. Semaglutide (Wegovy)
- 5.3.2.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
- 5.3.3. Topiramate (Xenical Alli)
- 5.3.3.1. Global Anti-Obesity Medication Market, by Topiramate (Xenical Alli), by Region, 2019-2032 (USD Million)
- 5.3.4. Dulaglutide (Trulicity)
- 5.3.4.1. Global Anti-Obesity Medication Market, by Dulaglutide (Trulicity), by Region, 2019-2032 (USD Million)
- 5.3.5. Liraglutide (Semaglutide (Wegovy))
- 5.3.5.1. Global Anti-Obesity Medication Market, by Liraglutide (Semaglutide (Wegovy)), by Region, 2019-2032 (USD Million)
- 5.3.6. Others
- 5.3.6.1. Global Anti-Obesity Medication Market, by Others, by Region, 2019-2032 (USD Million)
- 5.4. Approved
- 5.4.1. Global Anti-Obesity Medication Market, by Approved, by Region, 2019-2032 (USD Million)
- 5.4.2. Liraglutide (Orlistat)
- 5.4.2.1. Global Anti-Obesity Medication Market, by Liraglutide (Orlistat), by Region, 2019-2032 (USD Million)
- 5.4.3. Bupropion-naltrexone (Contrave)
- 5.4.3.1. Global Anti-Obesity Medication Market, by Bupropion-naltrexone (Contrave), by Region, 2019-2032 (USD Million)
- 5.4.4. Orlistat
- 5.4.4.1. Global Anti-Obesity Medication Market, by Orlistat, by Region, 2019-2032 (USD Million)
- 5.4.4.2. Alli
- 5.4.4.2.1. Global Anti-Obesity Medication Market, by Alli, by Region, 2019-2032 (USD Million)
- 5.4.4.3. Xenical
- 5.4.4.3.1. Global Anti-Obesity Medication Market, by Xenical, by Region, 2019-2032 (USD Million)
- 5.4.5. Setmelanotide (Imcivree)
- 5.4.5.1. Global Anti-Obesity Medication Market, by Setmelanotide (Imcivree), by Region, 2019-2032 (USD Million)
- 5.4.6. Tirzepatide (Zepbound)
- 5.4.6.1. Global Anti-Obesity Medication Market, by Tirzepatide (Zepbound), by Region, 2019-2032 (USD Million)
- 5.4.7. Phentermine-topiramate (Qsymia)
- 5.4.7.1. Global Anti-Obesity Medication Market, by Phentermine-topiramate (Qsymia), by Region, 2019-2032 (USD Million)
- 5.4.8. Semaglutide (Wegovy)
- 5.4.8.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
6. Global Anti-Obesity Medication Market, by Mechanism of Action
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 6.3. Centrally Acting Drugs
- 6.3.1. Global Anti-Obesity Medication Market, by Centrally Acting Drugs, by Region, 2019-2032 (USD Million)
- 6.4. Peripherally Acting Drugs
- 6.4.1. Global Anti-Obesity Medication Market, by Peripherally Acting Drugs, by Region, 2019-2032 (USD Million)
7. Global Anti-Obesity Medication Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Anti-Obesity Medication Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Global Anti-Obesity Medication Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
- 7.5. Others
- 7.5.1. Global Anti-Obesity Medication Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Anti-Obesity Medication Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Anti-Obesity Medication Market - North America
- 8.3.1. North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.3.2. North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.3. North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.3.4. Anti-Obesity Medication Market - U.S.
- 8.3.4.1. U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.3.5. Anti-Obesity Medication Market - Canada
- 8.3.5.1. Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4. Anti-Obesity Medication Market - Europe
- 8.4.1. Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.2. Europe.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.3. Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.4. Anti-Obesity Medication Market - UK
- 8.4.4.1. UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.4.3. UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.5. Anti-Obesity Medication Market - France
- 8.4.5.1. France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.5.2. France.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.5.3. France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.6. Anti-Obesity Medication Market - Germany
- 8.4.6.1. Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.7. Anti-Obesity Medication Market - Italy
- 8.4.7.1. Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.8. Anti-Obesity Medication Market - Spain
- 8.4.8.1. Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.9. Anti-Obesity Medication Market - Netherlands
- 8.4.9.1. Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.4.10. Anti-Obesity Medication Market - Russia
- 8.4.10.1. Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5. Anti-Obesity Medication Market - Asia Pacific
- 8.5.1. Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5.4. Anti-Obesity Medication Market - China
- 8.5.4.1. China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.4.2. China.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.4.3. China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5.5. Anti-Obesity Medication Market - India
- 8.5.5.1. India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.5.2. India.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.5.3. India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5.6. Anti-Obesity Medication Market - Malaysia
- 8.5.6.1. Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5.7. Anti-Obesity Medication Market - Japan
- 8.5.7.1. Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5.8. Anti-Obesity Medication Market - Indonesia
- 8.5.8.1. Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.5.9. Anti-Obesity Medication Market - South Korea
- 8.5.9.1. South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.6. Anti-Obesity Medication Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.6.4. Anti-Obesity Medication Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.6.5. Anti-Obesity Medication Market - UAE
- 8.6.5.1. UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.6.6. Anti-Obesity Medication Market - Israel
- 8.6.6.1. Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.6.7. Anti-Obesity Medication Market - South Africa
- 8.6.7.1. South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.7. Anti-Obesity Medication Market - Latin America
- 8.7.1. Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.3. Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.7.4. Anti-Obesity Medication Market - Mexico
- 8.7.4.1. Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.7.5. Anti-Obesity Medication Market - Brazil
- 8.7.5.1. Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
- 8.7.6. Anti-Obesity Medication Market - Argentina
- 8.7.6.1. Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Boehringer Ingelheim International GmbH
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Currax Pharmaceuticals
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Gelesis
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. GlaxoSmithKline plc
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Kintai Therapeutics
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Novartis AG
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Novo Nordisk A/S
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Rhythm Pharmaceuticals, Inc
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. VIVUS LLC
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
